BRAF gene

Overview

The BRAF gene (B-Raf proto-oncogene, serine/threonine kinase) encodes a cytoplasmic kinase that is a central node in the RAS–RAF–MEK–ERK mitogen-activated protein kinase (MAPK) signaling cascade. This pathway transduces extracellular growth signals into nuclear transcriptional programs governing cell proliferation, differentiation, and survival. BRAF phosphorylates and activates MEK1/2, which in turn phosphorylates ERK1/2, propagating mitogenic signals downstream to effectors such as p90RSK. Somatic mutations in BRAF—most notably the V600E substitution, wherein valine is replaced by glutamate at codon 600—constitutively activate kinase activity independent of upstream RAS input, driving uncontrolled tumor cell proliferation. Oncogenic BRAF alterations are found across a broad spectrum of human malignancies including melanoma, papillary thyroid carcinoma, glioma, and pancreatic cancer, establishing BRAF as one of the most clinically actionable oncogenes in modern precision oncology.

Beyond V600E, the BRAF locus harbors a spectrum of rarer activating mutations and structural rearrangements that vary in their functional consequences and therapeutic sensitivities. Cross-talk between BRAF and parallel survival pathways—particularly the PI3K/AKT axis involving Akt1—means that oncogenic BRAF signaling is rarely isolated, and co-occurring alterations in genes such as KRAS can modulate both tumor behavior and responsiveness to targeted inhibition. The clinical significance of BRAF is underscored by the approval of multiple small-molecule BRAF inhibitors and their combinations with MEK inhibitors, which have transformed outcomes in BRAF V600E-driven cancers.

Focus of Latest Publications

Recent publications on BRAF gene continue to emphasize its central role in MAPK pathway-driven oncogenesis and in the clinical management of BRAF-altered cancers. A joint SNO/EANO consensus review synthesized current evidence for adults and children with BRAF-altered glioma, highlighting the growing use of molecular diagnostics to identify oncogenic BRAF alterations across WHO grades. The review discussed when to test for BRAF alterations, how to select and monitor targeted therapies, management of treatment-related toxicities, approaches to resistance, and areas where evidence remains limited, with the goal of providing practical guidance while identifying priorities for future prospective studies.

Several studies focused on BRAF-targeted therapy and resistance mechanisms in melanoma and lung cancer. In melanoma, a nationwide Italian study examined rare BRAF mutations and found that they were uncommon but clinically relevant, with some variants outside codon 600 still associated with altered BRAF kinase activity. Outcomes with BRAF/MEK inhibitor therapy in rare BRAF-mutant melanoma were broadly comparable to V600E/K-mutant disease, although response rates were numerically lower. Another study identified FGD1 as a contributor to secondary resistance to BRAF inhibition in BRAF V600E-mutated melanoma cells; FGD1 knockdown reduced proliferation, promoted resistance to BRAF inhibition, and increased sensitivity to p21-activated kinase inhibition, while prolonged BRAF inhibitor exposure was associated with reduced FGD1 levels and adaptive resistance features. In EGFR-mutated advanced NSCLC progressing on first-line osimertinib, the ORCHARD platform study evaluated osimertinib plus selumetinib in patients with BRAF alterations, reflecting interest in MEK inhibition as a strategy to address resistance-associated BRAF pathway changes.

Other recent work expanded the therapeutic and safety landscape of BRAF-directed treatment. A medicinal chemistry study designed pyrimidino[4,5-d]pyrimidine-based compounds as B-RAF V600E inhibitors and identified one compound with selective biochemical binding to B-RAF V600E, although cellular antiproliferative activity was modest, suggesting possible limitations in permeability or efflux. Real-world pharmacovigilance analysis of BRAF and MEK inhibitors showed that cutaneous adverse drug reactions are common and vary substantially by agent, with rash as the predominant event and notable differences in photosensitivity and dermatitis acneiform reporting across drugs. Together, these studies underscore both the therapeutic promise of BRAF targeting and the need for improved resistance management and toxicity monitoring.

A smaller set of publications addressed BRAF in other tumor contexts. One study examined the molecular characteristics of BRAF-mutant papillary thyroid cancer in relation to isthmus topography, reflecting ongoing interest in how tumor location may relate to molecular features. Across these reports, BRAF remains a key biomarker and therapeutic target, with recent literature spanning consensus-based clinical management, mutation spectrum characterization, inhibitor development, resistance biology, and real-world safety surveillance.

Key Publications

NEWJun BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. (Neuro-oncology, 2026, PMID 42261252): "Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics."
Jun Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. (ChemMedChem, 2026, PMID 42208521): "B-RAF, a key kinase in this pathway, is frequently mutated, with the B-RAF V600E variant being highly prevalent in melanoma."
May Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. (European journal of cancer (Oxford, England : 1990), 2026, PMID 42202477): "We report final results of the module assessing the efficacy and safety of osimertinib plus selumetinib (a MEK inhibitor) in patients with BRAF alterations."
May Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. (Clinical pharmacology and therapeutics, 2026, PMID 42177750): "BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600-mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity."
May Effects of Isthmus Topography on the Molecular Characteristics of BRAF-mutant Papillary Thyroid Cancer. (Cancer genomics & proteomics, 2026, PMID 42055630): "This study aimed to characterize the molecular features of isthmus thyroid cancer."
May Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI). (Pigment cell & melanoma research, 2026, PMID 42003243): "This study investigated the distribution, prognostic role, and functional impact of rare BRAF mutations in melanoma."
Apr FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma. (Melanoma research, 2026, PMID 41802101): "FGD1 knockdown in BRAF V600E-mutated melanoma cell lines reduces cell proliferation and induces secondary resistance to BRAF inhibition, while increasing sensitivity to p21-activated kinase inhibition."